Distribution of Traditional and Novel Risk Factors and Their Relation to Subsequent Cardiovascular Events in Patients With Acute Coronary Syndromes (from the PROVE IT-TIMI 22 Trial)

被引:18
作者
Acharjee, Subroto [2 ]
Qin, Jie [1 ]
Murphy, Sabina A. [1 ]
McCabe, Carolyn [1 ]
Cannon, Christopher P. [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div,Dept Med, Boston, MA 02115 USA
[2] SUNY Buffalo, Dept Med, Sch Med, Buffalo, NY 14260 USA
关键词
C-REACTIVE PROTEIN; HEART-DISEASE; CHOLESTEROL LEVELS; FOLLOW-UP; PREDICTION; MEN; WOMEN;
D O I
10.1016/j.amjcard.2009.10.042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current guidelines recommend risk stratification largely based on traditional risk factors such as those in the Framingham Risk Score. We studied the distribution of 12 traditional and non-traditional risk markers (age >= 65 years, male gender, family history of premature coronary heart disease, low-density lipoprotein cholesterol >= 70 mg/di, high-density lipoprotein cholesterol <40 mg/di in men and <50 mg/dl in women, systolic blood pressure > 130 mm Hg, diabetes mellitus, smoking, C-reactive protein >= 2 mg/L, triglycerides >150 mg/di, prediabetes defined as a fasting glucose level 100 to 125 mg/di or hemoglobin Ale >6, and obesity defined as body mass index >= 30 kg/m(2)) in 3,675 patients from the PROVE IT-TIMI 22 trial at 4 months and evaluated the risk of cardiovascular events stratified by the number of risk factors. The median number of risk factors was 5. In individual risk factor subgroups, men, smokers, hypertensives, and patients with increased low-density lipoprotein cholesterol had just that added risk factor compared to their counterparts (median 5 vs 4). In contrast, patients with diabetes, prediabetes, and increased triglycerides, C-reactive protein, or body mass index had not only that, but also another added risk factor (median 6 vs 4). A higher risk factor count was strongly related with increased rate of death, myocardial infarction, unstable angina, stroke, or revascularization, from 0% to 38.6% at 2 years for 0 to >= 9 risk factors (p < 0.0001). In conclusion, with the observed "clustering" of risk factors and the link between increasing risk factor count and adverse outcomes in a patient with 1 diagnosed risk factor, a comprehensive review of traditional and novel risk factors is important to fully assess cardiovascular risk. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:619-623)
引用
收藏
页码:619 / 623
页数:5
相关论文
共 23 条
[1]   High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men -: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study [J].
Balkau, B ;
Shipley, M ;
Jarrett, RJ ;
Pyörälä, K ;
Pyörälä, M ;
Forhan, A ;
Eschwège, E .
DIABETES CARE, 1998, 21 (03) :360-367
[2]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[3]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[4]  
Collins R, 2003, LANCET, V361, P2005
[5]   Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study [J].
Deedwania, Prakash ;
Barter, Philip ;
Carmena, Rafael ;
Fruchart, Jean-Charles ;
Grundy, Scott M. ;
Haffner, Steven ;
Kastelein, John J. P. ;
LaRosa, John C. ;
Schachner, Holly ;
Shepherd, James ;
Waters, David D. .
LANCET, 2006, 368 (9539) :919-928
[6]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[7]   Major risk factors as antecedents of fatal and nonfatal coronary heart disease events [J].
Greenland, P ;
Knoll, MD ;
Stamler, J ;
Neaton, JD ;
Dyer, AR ;
Garside, DB ;
Wilson, PW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07) :891-897
[8]  
Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014
[9]   Prevalence of conventional risk factors in. patients with coronary heart disease [J].
Khot, UN ;
Khot, MB ;
Bajzer, CT ;
Sapp, SK ;
Ohman, EM ;
Brener, SJ ;
Ellis, SG ;
Lincoff, AM ;
Topol, EJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07) :898-904
[10]   Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial [J].
Morrow, David A. ;
de Lemos, James A. ;
Sabatine, Marc S. ;
Wiviott, Stephen D. ;
Blazing, Michael A. ;
Shui, Amy ;
Rifai, Nader ;
Califf, Robert M. ;
Braunwald, Eugene .
CIRCULATION, 2006, 114 (04) :281-288